PXD065812

PXD065812 is an original dataset announced via ProteomeXchange.

Title	Proteomic Profiling of Colorectal Liver Metastases Reveals Histopathological Response-Specific Molecular Signatures of Chemotherapy Efficacy
Description	Background: Chemoresistance in treatment of colorectal liver metastases (CRLM) poses a serious challenge in preventing disease relapse, with up to 80% of patients developing drug resistance over the course of treatment. Proteomic signatures of responsive vs. non-responsive metastases can provide insights into functional expression patterns, potentially identifying biomarkers for therapy efficacy. Methods: A total of 33 CRLM tissue samples from 31 patients were subjected to histopathological and proteomic analysis. The patients were included in the study after undergoing preoperative treatment (n = 28), including platinum-based chemotherapy (n = 19), non-platinum-based chemotherapy (n = 8), as well as targeted therapies (n = 20), or without preoperative therapy (n = 5). Based on Rubbia-Brandt criteria and vital tumor cell percentage, CRLM were categorized to major (MR), partial (PR) and no response (NR) groups. Proteomic analysis was conducted using label-free mass spectrometry (LFQ-MS), followed by clustering according to histological response and distinct treatment regimens. Results: Proteomic analysis revealed significant differential protein expression of 607 proteins linked to distinct histopathological response types. CRLM responsive to chemotherapy displayed marked enrichment (p ≤ 0.01) in pathways associated with immune infiltration, complement system, ECM matrix organization and apolipoprotein-associated processes, indicative of distinct stromal and immune invasion patterns with multimodal importance of cell adhesion proteins. In contrast, attenuated expression of proteins enriched in pathways of mitochondrial translation initiation, elongation and termination was detectable. Conclusion: CRLM exhibited distinct proteomic phenotypes based on their histopathological response to preoperative systemic therapy largely independent of chemotherapy regimens. This proteomic profiling establishes a foundation for identifying critical profiles and enhancing our understanding of mechanisms driving tumor response.
HostingRepository	PRIDE
AnnounceDate	2026-04-13
AnnouncementXML	Submission_2026-04-12_20:02:11.521.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Karl Hillebrandt
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	No PTMs are included in the dataset
Instrument	autoflex

Revision	Datetime	Status	ChangeLog Entry
0	2025-07-06 08:00:37	ID requested
⏵ 1	2026-04-12 20:02:12	announced

B, ö, hm AK, Skrip LM, Klein O, Strobl F, Wieland JK, Arnold A, Zhou Y, Papke B, Sers C, Modest DP, Moosburner S, Haber PK, Krenzien F, Raschzok N, Sch, ö, ning W, Horst D, Malinka T, Sack I, Pratschke J, Sauer IM, Hillebrandt KH, Proteomic profiling of colorectal liver metastases reveals histopathological response-specific molecular signatures of chemotherapy efficacy. J Transl Med, 24(1):(2026) [pubmed]

10.1186/s12967-026-07945-1;

submitter keyword: Human

CRLM

CRC

Karl Hillebrandt
contact affiliation	Charité Univeristätsmedizin Berlin, Department of Surgery, Augustenburger Platz 1, 13353 Berlin
contact email	karl-herbert.hillebrandt@charite.de
lab head
Karl Hillebrandt
contact affiliation	Department of Surgery
contact email	karl-herbert.hillebrandt@charite.de
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/04/PXD065812

PRIDE project URI

• PRIDE
  1. PXD065812
     1. Label: PRIDE project
     2. Name: Proteomic Profiling of Colorectal Liver Metastases Reveals Histopathological Response-Specific Molecular Signatures of Chemotherapy Efficacy